Article Information
vol. 10 no. 480
PubMed:
Published By:
Print ISSN:
Online ISSN:
History:
- Received August 22, 2016
- Accepted May 5, 2017
- .
Copyright & Usage:
Copyright © 2017, American Association for the Advancement of Science
Research ArticleBiochemistry
Key determinants of selective binding and activation by the monocyte chemoattractant proteins at the chemokine receptor CCR2
- Zil E. Huma1,
- Julie Sanchez1,
- Herman D. Lim2,
- Jessica L. Bridgford1,2,
- Cheng Huang1,
- Bradyn J. Parker1,
- Jiann G. Pazhamalil1,
- Benjamin T. Porebski1,
- Kevin D. G. Pfleger3,
- J. Robert Lane2,
- Meritxell Canals2,*, and
- Martin J. Stone1,*
- 1Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.
- 2Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
- 3Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research, QEII Medical Centre; and Centre for Medical Research, University of Western Australia, Crawley and Dimerix Bioscience Limited, Nedlands, Western Australia, Australia.
- ↵*Corresponding author. Email: martin.stone{at}monash.edu (M.J.S.); meri.canals{at}monash.edu (M.C.)
See allHide authors and affiliations
Science Signaling 23 May 2017:
Vol. 10, Issue 480, eaai8529
DOI: 10.1126/scisignal.aai8529
Vol. 10, Issue 480, eaai8529
DOI: 10.1126/scisignal.aai8529
Zil E. Huma
Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.
Julie Sanchez
Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.
Herman D. Lim
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Jessica L. Bridgford
Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Cheng Huang
Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.
Bradyn J. Parker
Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.
Jiann G. Pazhamalil
Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.
Benjamin T. Porebski
Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.
Kevin D. G. Pfleger
Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research, QEII Medical Centre; and Centre for Medical Research, University of Western Australia, Crawley and Dimerix Bioscience Limited, Nedlands, Western Australia, Australia.
J. Robert Lane
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Meritxell Canals
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Martin J. Stone
Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.
